Aquestive Therapeutics, Inc. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Aquestive Therapeutics appointed Richard Daly to its Board of Directors effective October 14, 2026, expanding the board from seven to eight members (seven independent). Daly is a 30+ year life sciences executive with CEO and senior commercial experience at AstraZeneca, Takeda, Catalyst Pharmaceuticals, and other biotech firms. The appointment is explicitly tied to preparing for potential FDA approval and commercial launch of Anaphylm (dibutepinephrine sublingual film) for severe allergic reactions.
Why this rating
Board appointment is routine governance; Daly's expertise is relevant to Anaphylm launch but no binding commitments, capital, or operational changes disclosed. Moderate positive signal but immaterial to $291.6M company fundamentals.
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.